Physician attitudes about non-medical switching to biosimilars: results from an online physician survey in the United States

Teeple, Amanda; Ellis, Lorie; Huff, Laura; Reynolds, Caroline; Ginsburg, Shiphra; Howard, Leah; Walls, Deborah G.; Curtis, Jeffrey R.

doi:10.1080/03007995.2019.1571296

Cited by 53 publications

(59 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After screening for eligibility, we included 16 studies in the analysis ( Table 2 ) [ 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 ]. The included studies were from Europe, UK, United States, Australia, Asia, and Africa [ 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 ]. The targeted healthcare professionals were: clinicians, GPs, pharmacists, nurses, consultants, care managers, and specialists in clinical settings where biologics are more involved such as oncology, rheumatology, endocrinology, gastroenterology, dermatology, nephrology, and hematology.…”

Section: Resultsmentioning

confidence: 99%

“…In seven studies [ 21 , 22 , 27 , 29 , 31 , 33 , 34 ], we found that healthcare professionals had a good knowledge of biosimilars, and at least know the basic concepts of them. However, healthcare professionals were not satisfactorily familiar with concepts and the processes of interchangeability, extrapolation and pharmacovigilance.…”

Section: Resultsmentioning

confidence: 99%

“…The Russian study found that only 20% of clinicians considered that biosimilars are not equal to generics [ 25 ]. However, Teeple et al reported that 88% of rheumatologists, dermatologists and gastroenterologists knew what biosimilars are [ 27 ]. The study from Spain found that only 27% of primary care physicians know the difference between generics and biosimilars, and 84% of them do not understand biosimilar clinical development [ 28 ].…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Clinical and Regulatory Concerns of Biosimilars: A Review of Literature

Halimi

Daci

Netkovska

et al. 2020

IJERPH

View full text Add to dashboard Cite

Although biosimilars have been part of clinical practice for more than a decade, healthcare professionals (HCPs) do not fully accept them. This is because of the perception that biosimilars may not be like their originators in terms of quality, safety, and efficacy. This study aims to evaluate the current knowledge and attitudes of healthcare professionals toward biosimilar prescription, and to elaborate on their concerns. We reviewed the literature using PubMed, Cochrane Library, and Science Direct electronic databases in the period from 2018 to 2020. The knowledge and confidence of healthcare professionals vary between countries, between clinical profiles and between studies. Although most of the healthcare professionals had a positive attitude to prescribing biosimilars, they would still prefer to prescribe them in initial treatment. Generally, HCPs were against multiple switches and substitution of biosimilars at the pharmacy level. HCP’s key concern was interchangeability, with eventual consequences on the clinical outcome of patients. HCPs still approach biosimilars with caution and stigma. HCPs need to have an unbiased coherent understanding of biosimilars at clinical, molecular and regulatory levels. It was also observed that most of their concerns are more theoretical than science-based. Physicians are in an excellent position to accept biosimilars, but they need the additional support of regulatory authorities to approve and take into consideration the available scientific data regarding biosimilars.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Clinical and Regulatory Concerns of Biosimilars: A Review of Literature

Halimi

Daci

Netkovska

et al. 2020

IJERPH

View full text Add to dashboard Cite

show abstract

“…10−12 Switching from originator biologics to biosimilars remains a topic of scientific interest. 13 Switching among biologics for reasons unrelated to effectiveness and tolerability, such as cost, is known as non-medical switching (NMS). NMS occurs very rarely among different originator biologics because of poor outcomes.…”

Section: Introductionmentioning

confidence: 99%

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab

Fitzgerald

Melsheimer

Lafeuille

et al. 2021

BTT

View full text Add to dashboard Cite

“…The growing body of evidence for biosimilars is also leading to suggestions to modify the current lengthy approval process and costs to enhance earlier access and strengthen competition (46). There are though still concerns with switching among physicians that need to be addressed with education as these can negatively impact on their future utilisation (47)(48)(49). Additional monitoring of patient outcomes in routine clinical practice should help further reduce possible concerns as well as potentially reduce the need for comparative clinical efficacy evidence as more originators lose their patents.…”

mentioning

confidence: 99%

Ever-changing landscape of biosimilars in Canada; findings and implications from a global perspective

Godman

Allocati²,

Moorkens

2019

GaBI J

View full text Add to dashboard Cite

Siu et al. have comprehensively assessed the rapidly changing regulation and reimbursement environment for biologicals and biosimilars in Canada and the resultant implications. Brian Godman, Eleonora Allocati and Evelien Moorkens review the paper by Siu et al. regarding the evolving regulatory and reimbursement landscape in Canada (1), and subsequently link these within the broader global context of biosimilar market access to stimulate future activities and debates in this important area. This includes the current and potential market value of biosimilars, their regulatory and reimbursement environments as well as ongoing initiatives across countries to enhance their utilisation to maximise potential savings. In addition, the potential sustainability of appreciable discounts among both originator and biosimilar manufacturers. Siu et al. point out that biologics are now commonly prescribed medicines for a wide variety of disease areas including diabetes, immunological diseases such as arthritis, inflammatory bowel disease, and psoriasis, as well as for a number of cancers (1-4). Their high prices coupled with the prevalence of these diseases have resulted in considerable sales. Worldwide sales of cancer medicines, many of which are biologicals, was US$107billion in 2015 and rising (5, 6). The global anti TNF market was valued at US$ 40.4 billion in 2017, and expected to expand at 2.54% per year with Europe and the US currently accounting for 87.7% of sales (7).

show abstract

Physician attitudes about non-medical switching to biosimilars: results from an online physician survey in the United States

Cited by 53 publications

References 10 publications

Clinical and Regulatory Concerns of Biosimilars: A Review of Literature

Clinical and Regulatory Concerns of Biosimilars: A Review of Literature

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab

Ever-changing landscape of biosimilars in Canada; findings and implications from a global perspective

Contact Info

Product

Resources

About